New vaccine could help treat children with skin disease

The researchers said their findings provide an early map for developing treatments that can effectively and targetedly reduce recurrent eczema flare-ups.

“The interaction between Staphylococcus aureus and eczema has been known for decades, but new scientific approaches continue to make important discoveries about the complex relationship between these bacteria and the human response to them. ” he said. alan irvinA professor of dermatology at Trinity University said in a statement: “Our study outlines new findings about how children with eczema respond immunologically to infection with this common bacteria.”

Rachel McLaughlinProfessor of Immunology at Trinity University and senior author of the study said the group identified an overall pattern of immunosuppression associated with flare-ups of infected eczema., As a result, specific T cells, which are essential for mounting an effective immune response, are suppressed.

“Further work is needed to widen the scope of these results by expanding coverage to more people,” McLoughlin said in a statement. “This will help us see whether the patterns identified are consistent across different age groups and among subgroups with higher ethnic diversity.”

Dr. Leslie Youngsaid the pediatrician and primary care physician at MemorialCare Medical Group in Lakewood, California. Today's medical news The two most important approaches to controlling eczema today are to prevent the skin from becoming excessively dry and to reduce the skin irritation caused by dryness.

“Because eczema is a chronic disease and the tendency of the skin to respond to dryness is determined by genetics and immune response, these strategies are only temporary measures to calm temporary flare-ups,” the study said. said Young, who was not involved. .

“Inflammation is usually controlled with topical steroids or immune inhibitors, both of which can cause serious side effects when used chronically,” Young says. “If an infection is contributing to eczema worsening, oral antibiotics are often used to stop the infection. All of these treatments are only effective in the short term.”

Young said the vaccine could help people whose eczema is caused by infection.

“I would be hesitant to recommend this vaccine to people who have never had eczema, because staphylococci colonize the skin of many healthy people and are often harmless,” Young said. Ta. “The natural presence of this bacteria on healthy skin helps prevent the overgrowth of harmful bacteria. I am concerned about the unintended effects of altering the natural bacterial population on healthy skin. Masu.”

Dr. J. Wes Ulmsaid a medical researcher and bioinformatics expert who works as an analyst for the National Institutes of Health. Today's medical news This research is an interesting and potentially promising approach to disease management, and although still in its early stages, it “could help open up a wider range of tailored interventions for eczema and similar conditions.” It is said that

“Moisturizers and corticosteroid ointments are the mainstay of treatment, but other topical creams containing substances such as PDE-4 are also used.” [inhibitors] or calcineurin inhibitor “Things that help reduce the immune and inflammatory responses that cause eczema are becoming more common,” said Ulm, who was not involved in the study. “Typically, especially for childhood eczema, the first treatment is to rehydrate the skin to reduce dryness. However, in more severe cases, phototherapy, which inhibits enzyme activity, and JAK Treatment with inhibitors is required. janus kinaseSubcutaneous (under the skin) biologics may also be an option if they exacerbate a erroneous immune response. ”

Ulm added that vaccination is unlikely to be used as a preventive measure because eczema causes and develops differently in different people.

“Having said that, further research will show that subpopulations (perhaps genetically sensitive that make them particularly susceptible to more severe cases of eczema) may benefit from vaccine-based approaches to preventing the onset of the disease in the first place.” “It is possible that a cohort of patients with the mutation will be identified,” he said.